ABCL AbCellera Biologics Inc.

NASDAQ
$12.70

AbCellera Biologics Inc. (ABCL) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +119.3% since its last earnings release on August 5, 2026.

AbCellera Biologics Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.18)
Rev est $6.14M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.74

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.